SUO 2023
SUO 2023
Advertisement
Ariana L. Smith, MDSUO 2023 | December 20, 2023
Drs. Smith and Wallis shed light on how urologists can reduce risks and improve the well-being of their female patients.
Read More
Seth Lerner, MD, FACSNon-Muscle Invasive Urothelial Carcinoma | December 18, 2023
Dr. Lerner shares his thoughts on the results of ENVISION and the potential for UGN-102 for lg/ir NMIBC.
Seth Lerner, MD, FACSMuscle Invasive Urothelial Carcinoma | December 18, 2023
Dr. Lerner explains what the SWOG S1011 study suggests about the outcomes benefit of standard versus extended LND for MIBC.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 18, 2023
Drs. Joyce and Wallis consider the impact of financial toxicity and containing costs for patients with GU malignancies.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | December 18, 2023
Drs. Pal and Wallis break down the role of the microbiome and response in patients with kidney cancer.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | November 30, 2023
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.
Katy MarshallSUO 2023 | December 18, 2023
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Katy MarshallSUO 2023 | December 18, 2023
Investigators used multivariable analysis and Kaplan-Meier analysis to compare partial nephrectomy with radical nephrectomy.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | February 8, 2024
Drs. George and Wallis discuss applications and counseling patients on focal therapy, as well as post-treatment follow-up.
Emily MenendezSUO 2023 | December 18, 2023
The NODESAFE model can aid in clinical decision-making and may spur consideration for adjuvant therapy in patients with RCC.
Zachary BessetteSUO 2023 | December 18, 2023
Drs. Woldu and Pierorazio presented on disparities in RCC care and outcomes as well as appropriate AS in small renal masses.
Emily MenendezSUO 2023 | December 18, 2023
Enzalutamide plus leuprolide acetate and enzalutamide alone caused delayed MFS when compared with placebo plus leuprolide.
Emily MenendezSUO 2023 | January 3, 2024
An in vitro model of EV-resistant bladder cancer showed that EV resistance was mainly due to resistance of the payload MMAE.
Zachary BessetteSUO 2023 | November 29, 2023
Dr. McKiernan provided the argument for surveillance in the event of complete clinical response after NAC for MIBC.
Zachary BessetteSUO 2023 | December 18, 2023
Drs. Pierorazio and Eggener moderated a session on simultaneous optimization of organ transplant and GU cancer outcomes.
Katy MarshallSUO 2023 | November 29, 2023
Prior research has indicated that CIS may be a surrogate for measurable residual disease.
Katy MarshallSUO 2023 | November 29, 2023
In the retrospective study, patients underwent cross-sectional imaging, office cystoscopy, and office cytology.
Emily MenendezSUO 2023 | December 18, 2023
Single-port and multi-port RARP approaches were found to provide similar 1-year biochemical recurrence rates.
Emily MenendezSUO 2023 | January 31, 2024
Similar to results from the intention-to-treat population, pembrolizumab was favored for its benefit of prolonging DFS.
Katy MarshallSUO 2023 | November 29, 2023
The retrospective analysis evaluated the data of patients who underwent multiagent chemotherapy.
Advertisement
Advertisement
Advertisement